A handout file photo shows a technician holding a master H1N1 virus sample, for the pre-production of a vaccine against pandemic influenza A (H1N1) virus at a laboratory of GlaxoSmithKline in Dresden June 16, 2009. The pandemic of H1N1 swine flu has been a bonus for GlaxoSmithKline, which makes the inhaled flu drug Relenza, a vaccine and special antiviral masks, the company said July 23, 2009. Relenza is one of two drugs approved for use against H1N1. Picture taken June 16, 2009. REUTERS/GlaxoSmithKline/Handout (GERMANY HEALTH) FOR EDITORIAL USE ONLY. NOT FOR SALE FOR MARKETING OR ADVERTISING CAMPAIGNS